Vilnius, April 10, 2024: Caszyme, a leading biotechnology company developing CRISPR gene editing solutions, has opened a new, 1336 sqm, state-of-the-art facility.
Caszyme leverages deep expertise in computational biology-driven discovery and protein engineering-based development of novel nucleases, alongside mRNA synthesis and optimization capabilities, to enable companies and institutions across various industries to apply CRISPR gene editing technology. This strategic expansion aims to increase Caszyme’s capacity and support the development of new complementary competencies to meet the growing demand for gene editing-based platforms and products in the US, Europe, and Asia, as the global gene editing market size is expected to reach USD 29.93 billion by 2032.
Caszyme was established in 2017 by Dr. Monika Paule, Dr. Giedrius Gasiunas and Prof. Virginijus Šikšnys – a pioneer of CRISPR-Cas gene editing research. Over the last 7 years, Caszyme has rapidly advanced its excellence and capabilities as an enabling expert partner in CRISPR gene editing solutions, collaborating with multiple life science organizations aiming to enter the CRISPR field or expand their gene editing capabilities.
During the new facility opening event Caszyme Co-founder and CEO, Dr. Monika Paule comments: “I am very grateful to Caszyme co-founders Dr. Giedrius Gasiunas and Prof. Virginijus Šikšnys as well as the whole Caszyme team for our continuous endeavor to bring CRISPR based innovations to the market and enable our partners throughout multiple industries. Our new facility is a great representation of our achievements so far, it will enable us to perform more top-class research and development and will further advance our capacity to meet the growing demand for expert end-to-end CRISPR gene editing solutions.”
The opening was attended by many of Caszyme’s partners and key stakeholders, who unanimously praised the company’s achievements.
“We are delighted to have established a longstanding partnership with Caszyme and are thrilled to witness their significant expansion in capacity and capabilities. We look forward to fostering further collaboration and driving innovation together,” says Isaac Meek, Director of Business Development at New England Biolabs.
“As one of the first partners of Caszyme, I am extremely proud of what the company has achieved. It will be exciting to see the novel editing nucleases that are discovered and the new partnerships that will form with the capacity enabled by the new facility,” says Barbara Mazur, Strategic Advisor at Aliment Capital.
“This significant milestone for Caszyme not only signifies the company’s growth but also demonstrates the capabilities of Lithuanian talents in growing international businesses, highlighting the overall potential and maturity of the life sciences ecosystem in Lithuania,” says Donatas Staniulis, Executive Director at LithuaniaBIO.
-ends-
For more information visit www.caszyme.com
Contact: Karolina Makovskyte, karolina@caszyme.com
Media: Richard Hayhurst richard@rhacomms.eu